Core Insights - Amazon reported quarterly earnings of $1.59 per share, exceeding the Zacks Consensus Estimate of $1.35 per share, and showing an increase from $1.13 per share a year ago, representing an earnings surprise of 17.78% [1] - The company generated revenues of $155.67 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.72% and up from $143.31 billion year-over-year [2] - Amazon has consistently surpassed consensus EPS estimates over the last four quarters, achieving this four times [2] Earnings Performance - The earnings surprise for the previous quarter was 22.37%, with actual earnings of $1.86 per share compared to an expected $1.52 per share [1] - The current consensus EPS estimate for the upcoming quarter is $1.33, with projected revenues of $160.46 billion, and for the current fiscal year, the EPS estimate is $6.13 on revenues of $690.33 billion [7] Stock Performance and Outlook - Amazon shares have declined approximately 15.9% since the beginning of the year, contrasting with the S&P 500's decline of 5.3% [3] - The company's Zacks Rank is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Internet - Commerce industry, to which Amazon belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Viewpoint - Amgen reported quarterly earnings of $4.90 per share, exceeding the Zacks Consensus Estimate of $4.16 per share, and showing an increase from $3.96 per share a year ago, representing an earnings surprise of 17.79% [1][2] Financial Performance - The company achieved revenues of $8.15 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 2.47%, and up from $7.45 billion year-over-year [2] - Over the last four quarters, Amgen has exceeded consensus EPS estimates four times and topped revenue estimates three times [2] Stock Performance - Amgen shares have increased approximately 11.6% since the beginning of the year, contrasting with a decline of -5.3% in the S&P 500 [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $5.29 on revenues of $8.82 billion, and for the current fiscal year, it is $20.57 on revenues of $34.99 billion [7] - The outlook for the Medical - Biomedical and Genetics industry is favorable, ranking in the top 32% of over 250 Zacks industries, suggesting potential for outperformance [8]

Cumulus Media (CMLS) came out with a quarterly loss of $1.88 per share versus the Zacks Consensus Estimate of a loss of $1.29. This compares to loss of $0.85 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -45.74%. A quarter ago, it was expected that this radio station owner would post a loss of $0.58 per share when it actually produced a loss of $0.39, delivering a surprise of 32.76%.Over the last four quarters, the company h ...

Core Viewpoint - Sotera Health Company reported quarterly earnings of $0.14 per share, exceeding the Zacks Consensus Estimate of $0.12 per share, and showing a slight increase from $0.13 per share a year ago, indicating a 16.67% earnings surprise [1][2] Financial Performance - The company posted revenues of $254.52 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 3.63%, compared to $248.18 million in the same quarter last year [2] - Over the last four quarters, Sotera Health has exceeded consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Sotera Health shares have declined approximately 15.9% since the beginning of the year, while the S&P 500 has decreased by 5.3% [3] - The current Zacks Rank for Sotera Health is 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is $0.19 on revenues of $283.2 million, and for the current fiscal year, it is $0.75 on revenues of $1.13 billion [7] - The outlook for the Medical Services industry, where Sotera Health operates, is currently in the top 28% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]

Company Performance - Dun & Bradstreet reported quarterly earnings of $0.21 per share, exceeding the Zacks Consensus Estimate of $0.20 per share, and showing a year-over-year increase from $0.20 per share [1] - The company posted revenues of $579.8 million for the quarter ended March 2025, slightly missing the Zacks Consensus Estimate by 0.02%, but up from $564.5 million a year ago [2] - Over the last four quarters, Dun & Bradstreet has surpassed consensus EPS estimates only once and has topped consensus revenue estimates just once [2] Stock Movement and Outlook - Dun & Bradstreet shares have declined approximately 28% since the beginning of the year, compared to a decline of 5.3% for the S&P 500 [3] - The sustainability of the stock's price movement will largely depend on management's commentary during the earnings call [3] - The current consensus EPS estimate for the upcoming quarter is $0.24 on revenues of $595.09 million, and for the current fiscal year, it is $1.04 on revenues of $2.46 billion [7] Industry Context - The Business - Information Services industry, to which Dun & Bradstreet belongs, is currently ranked in the top 30% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The current estimate revisions trend for Dun & Bradstreet is mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6]

Huntington Ingalls (HII) came out with quarterly earnings of $3.79 per share, beating the Zacks Consensus Estimate of $2.90 per share. This compares to earnings of $3.87 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 30.69%. A quarter ago, it was expected that this shipbuilder would post earnings of $3.28 per share when it actually produced earnings of $3.15, delivering a surprise of -3.96%.Over the last four quarters, the co ...

Wayfair (W) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of a loss of $0.18 per share. This compares to loss of $0.32 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 155.56%. A quarter ago, it was expected that this online home goods retailer would post earnings of $0.02 per share when it actually produced a loss of $0.25, delivering a surprise of -1,350%.Over the last four quarters ...

Organon (OGN) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to earnings of $1.22 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 14.61%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $0.86 per share when it actually produced earnings of $0.90, delivering a surprise of 4.65%.Over the last four quarters, the com ...

Core Insights - Biogen Inc. reported quarterly earnings of $3.02 per share, missing the Zacks Consensus Estimate of $3.26 per share, and down from $3.67 per share a year ago, representing an earnings surprise of -7.36% [1] - The company posted revenues of $2.43 billion for the quarter, exceeding the Zacks Consensus Estimate by 8.91%, and up from $2.29 billion year-over-year [2] - Biogen shares have declined approximately 20.8% since the beginning of the year, compared to a decline of -5.3% for the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $4.10 on revenues of $2.33 billion, and for the current fiscal year, it is $15.63 on revenues of $9.17 billion [7] - The estimate revisions trend for Biogen is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Biogen belongs, is currently in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Puma Biotech, is expected to report quarterly earnings of $0.02 per share, reflecting a year-over-year change of +140%, with revenues anticipated at $43.96 million, up 0.4% from the previous year [9][10]

Core Viewpoint - Iron Mountain (IRM) reported quarterly earnings of $1.17 per share, exceeding the Zacks Consensus Estimate of $1.16 per share, and showing significant growth from $0.43 per share a year ago, indicating a positive earnings surprise of 0.86% [1] Financial Performance - The company posted revenues of $1.59 billion for the quarter ended March 2025, which was below the Zacks Consensus Estimate by 0.40%, but an increase from $1.48 billion year-over-year [2] - Over the last four quarters, Iron Mountain has surpassed consensus EPS estimates only once, and it has topped consensus revenue estimates two times [2] Stock Performance - Iron Mountain shares have declined approximately 14.7% since the beginning of the year, contrasting with the S&P 500's decline of 5.3% [3] - The current Zacks Rank for Iron Mountain is 5 (Strong Sell), indicating expectations of underperformance in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.20 on revenues of $1.67 billion, and for the current fiscal year, it is $4.91 on revenues of $6.74 billion [7] - The trend for estimate revisions ahead of the earnings release was unfavorable, which may impact future stock movements [6] Industry Context - The Business - Information Services industry, to which Iron Mountain belongs, is currently in the top 30% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]